CERS · Cerus
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $2.44
Note written ·
Price against the kill line
18.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $2.44, on record since 11 November 2026. The shares are down 33.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $2.44, the highest close of the last 20 sessions (29 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 2 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 57.7
- Revenue, change on a year (%)
- +9.5
- Operating margin (%)
- 0.7
- Free cash flow, four quarters ($M)
- 0.5
- Net cash, cash less debt ($M)
- −6.2
- Enterprise value to sales (×)
- 1.6
- Free-cash-flow yield (%)
- 0.1
All filed numbers
What Cerus reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 57.7 | +9.5 | 0.7 |
| first filed | 57.4 | +9.5 | −3.2 |
| first filed | 53.7 | +24.1 | −0.7 |
| first filed | 85.4 | — | −0.8 |
| first filed | 52.7 | — | 2.3 |
| first filed | 52.4 | — | −6.5 |
| Pre-tax income ($M) | −0.5 |
| Net income ($M) four quarters: −7.3 | −0.6 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +5.1 |
| Operating cash flow ($M) | 3.5 |
| Capital spending ($M) | 3.0 |
| Free cash flow ($M) | 0.5 |
| Cash and short-term investments ($M) | 57.1 |
| Debt ($M) secured debt | 63.4 |
| Net cash, cash less debt ($M) | −6.2 |
| Deferred revenue ($M) −37.2% on a year | 1.4 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 30.6 |
| Inventory ($M) | 64.7 |
| Shareholders' equity ($M) | 75.7 |
| Market value ($M) | 401 |
| Enterprise value, market value plus net debt ($M) | 407 |
| Enterprise value to sales (×) | 1.6 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 5.3 |
| Free-cash-flow yield (%) | 0.1 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 8.2% of shares outstanding sold short, 9.4 days of average trading to cover, −5.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $3.1M |
The thesis
Cerus Corporation's red-cell trial succeeded but its shares fell anyway, closing at $1.95 on 10 November 2026, 40.5% below the 52-week high of $3.28; the case now turns on whether fourth-quarter product revenue reaches the $229–231 million full-year guide that management reaffirmed on 2 November 2026. The three-month price change is −31.3% (adjusted daily closes).
The 2 November 2026 report mixed good and bad. The Phase 3 RedeS trial met its primary endpoint, and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose to $5.7 million. Product revenue of $57.7 million grew 10%, and Benzinga's headline put that $3.99 million short of the $61.7 million analyst estimate. The story is well known: the main pending event, the RedeS readout, is now out, and the shares fell after it. The 14-day relative strength index (RSI) is 30.2 as of 10 November 2026, up from 20.0 on 15 October 2026.
Bullish and bearish views on Cerus Corporation
The bull case on Cerus Corporation (CERS), in brief: RedeS met its primary endpoint. The bear case: revenue missed the estimate.
Bull case
- RedeS met its primary endpoint. On 2 November 2026 Cerus said INTERCEPT red blood cells were non-inferior to conventional red cells on adjusted hemoglobin increment, with no statistically significant difference in treatment-emergent adverse events. Management said secondary endpoints remain under analysis.
- Profit rose in the quarter. Q3 2026 adjusted EBITDA was $5.7 million and operating cash flow was $3.0 million (Cerus Q3 2026 release, 2 November 2026). Cash and short-term investments were $57.1 million at 30 September 2026.
- Product gross margin improved from Q2. It was 52.4% in Q3 against 51.4% in Q2, though below 53.4% a year earlier. On the 2 November 2026 call management expected some relief in Q4 from recent U.S. dollar strength, according to a Webull transcript summary.
- Full-year guidance held. Cerus reaffirmed 2026 product revenue of $229–231 million (11–12% growth) and fibrinogen complex revenue of $23–25 million on 2 November 2026. Stock Analysis listed four analysts on 6 September 2026 with targets from $4.00 to $6.50.
Bear case
- Revenue missed the estimate. Product revenue grew 10% to $57.7 million in Q3, against $52.7 million a year earlier. Total revenue rose 6% to $64.0 million, and government contract revenue fell to $6.3 million from $7.5 million.
- Guidance was not raised. Management reaffirmed the range after raising it on 30 July 2026. A Webull transcript summary calculates that the range needs Q4 product revenue of about $60.2–62.2 million, above Q3's $57.7 million.
- European approval slipped. Management now expects CE Mark clearance for red blood cells in late 2027, with the full RedeS study report added to the French regulator's review (2 November 2026 call). The press release gave no efficacy figures and no U.S. filing date.
- A $150 million shelf was filed. Cerus filed a prospectus on 2 November 2026 to offer up to $150 million of securities over time. Management said the shelf refreshes an expiring one not used since 2021, and cash is $57.1 million against a $35.0 million term loan and $28.5 million drawn on the revolver.
- Operating costs are rising. Selling, general and administrative expenses were $21.9 million in Q3 2026 against $18.6 million a year earlier, and the platelet premarket approval application needs additional data, per management on 2 November 2026.
Price setup
The reference close on 10 November 2026 was $1.95. That is 40.5% below the 52-week high of $3.28, and below the $2.26 October low close of 15 October 2026. The shares closed at $2.42 on 28 October 2026, ahead of the report.
The RSI at 30.2 is near the oversold zone that preceded the October rebound. The prior rebound lasted two weeks and then reversed after the report. The $2.26 and $2.42 closes are the nearest levels above the price. Cerus announced its report date on 19 October 2026, and the shares fell after the report even though the trial succeeded.
Crowding evidence is limited. No insider selling or retail-attention data is available for this note. The $150 million shelf filing is the only equity-supply item that can be observed, and no sale under it has been reported.
Catalysts ahead
- ~December 2026 (est.): Full RedeS statistical analysis and clinical study report submission to the FDA, followed by an agency meeting. Sets the U.S. approval timeline for red blood cells; the date is unconfirmed and management called first-half 2027 a reasonable expectation.
- ~February 2027 (est.): Q4 and full-year 2026 report. Settles whether product revenue reaches the reaffirmed $229–231M guide and whether gross margin recovers from 52.4%.
- 31 December 2027 (window end): Company-expected CE Mark clearance for INTERCEPT red blood cells in Europe. Opens the European red-cell market; the timeline already slipped to late 2027.
What would change the view
A daily close above $2.44, the highest close of the last 20 sessions (29 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Cerus trades on its own regulatory and revenue news more than on any sector move, and no current theme carries the name. The four covering analysts mean one target change can shift consensus. Euro exposure links gross margin to the dollar-euro rate, which management named a headwind in both Q2 and Q3 2026. Small-cap medical-device and biotech shares are the nearest comparison group in risk appetite and financing conditions.
The evidence, claim by claim (8)
- Q3 2026 total revenue $64.0M (+6%), product revenue $57.7M (+10%), product gross margin 52.4% vs 53.4% a year earlier, adjusted EBITDA $5.7M, operating cash flow $3.0M. Cerus Q3 2026 results release (8-K Exhibit 99.1) · as of
- Cash, equivalents and short-term investments $57.1M; $35.0M term loan and $28.5M drawn on the revolver. Cerus Q3 2026 results release (8-K Exhibit 99.1) · as of
- FY2026 product revenue guidance of $229–231M (11–12% growth) and IFC revenue guidance of $23–25M reaffirmed. Cerus Q3 2026 results release (8-K Exhibit 99.1) · as of
- Phase 3 RedeS trial met its primary endpoint of non-inferiority in adjusted hemoglobin increment; no statistically significant difference in treatment-emergent adverse events. Cerus Q3 2026 earnings call, Webull transcript · as of
- Q3 sales of $57.714M missed the $61.7M analyst estimate. Benzinga headline, 2 November 2026 · as of
- Management expects CE Mark clearance for red blood cells in late 2027 and will add the full RedeS study report to the European submission. Cerus Q3 2026 earnings call, Webull transcript · as of
- Cerus filed a prospectus to offer up to $150M of securities from time to time; management called it a refresh of an expiring shelf not used since 2021. Company news 2 November 2026; Q3 2026 earnings call · as of
- Cerus closed at $1.95, 40.5% below the $3.28 52-week high, with RSI(14) at 30.2 and a three-month price change of −31.3%. Split/dividend-adjusted daily bars · as of
Sources
- CERUS CORP - Form 8-K - FY2026 · sec.gov ·
- Cerus (CERS) Q3 2026 Earnings Call Transcript · webull.com
- Cerus Corporation announces third quarter 2026 financial results · finviz.com
Related · shared themes
AZTA
Azenta
Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic…
AVTR
Avantor
Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins…
CRL
Charles River Laboratories International
Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised…
EMBC
Embecta
Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle…
See also · stocks to watch